+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
mRNA Vaccines Market - Global Forecast 2026-2032- Product Image
mRNA Vaccines Market - Global Forecast 2026-2032- Product Image
Sale

mRNA Vaccines Market - Global Forecast 2026-2032

  • Report

  • 191 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6055092
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The mRNA Vaccines Market is projected to reach USD 11.60 Billion in 2026. It is expected to continue growing at a CAGR of 12.26%, reaching USD 23.38 Billion by 2032.

mRNA Vaccines: Executive Summary and Strategic Context

mRNA vaccines use messenger RNA to instruct cells to produce an antigen that stimulates an immune response. Their development has demonstrated the value of platform-based vaccine technologies, flexible manufacturing, and rapid collaboration across research, regulatory, and public-health systems. The field now extends beyond the initial pandemic application toward additional infectious-disease and therapeutic opportunities, while evidence requirements, delivery technologies, and manufacturing quality remain central considerations.

Platform Maturation Is Reshaping mRNA Vaccine Development

The mRNA vaccine landscape is shifting from emergency-scale deployment toward broader lifecycle development and routine immunization planning. Key changes include greater attention to antigen design, thermostability, dose optimization, delivery systems, cold-chain practicality, and manufacturing consistency. Developers and public-health authorities are also placing more emphasis on durability of protection, variant response, equitable access, and clinical evidence across diverse populations. These shifts favor organizations that can connect discovery, formulation, clinical development, regulatory engagement, and reliable production rather than treating them as separate activities.

Artificial Intelligence Accelerates Design, Testing, and Manufacturing Decisions

Artificial intelligence can support mRNA vaccine programs by improving antigen-selection workflows, analyzing immune-response data, optimizing sequence and formulation candidates, and identifying manufacturing process variables. It can also assist clinical-trial recruitment, safety-signal review, quality control, and supply-chain planning. However, AI-generated outputs require laboratory validation, representative datasets, transparent governance, and regulatory documentation. The greatest practical value is likely to come from integrating AI with experimental platforms and expert review, not from replacing established biological, clinical, or quality-assurance controls.

Regional Differences Shape Access, Infrastructure, and Development Priorities

North America combines advanced biomedical research, regulatory capability, and established vaccine infrastructure, but must continue addressing affordability, demand variability, and public confidence. Latin America is balancing infectious-disease priorities with uneven procurement capacity, cold-chain constraints, and the need for stronger regional manufacturing and surveillance. Europe benefits from sophisticated research and health systems while navigating coordinated procurement, regulatory alignment, and differences in national immunization policy. The Middle East is investing in health-system modernization and biotechnology capacity, with access and specialized logistics remaining important. Africa continues to prioritize dependable supply, technology transfer, local production, and delivery infrastructure. Asia-Pacific spans highly diverse capabilities, from advanced manufacturing and research ecosystems to settings where distribution, financing, and workforce capacity are the primary constraints.

International Groups Influence Coordination, Regulation, and Supply Resilience

ASEAN cooperation is relevant to regional procurement, regulatory coordination, and manufacturing development across varied health systems. BRICS members bring substantial scientific, industrial, and public-health capabilities, while also facing differences in regulation, financing, and access. The European Union benefits from shared institutions and coordinated health initiatives, although national implementation remains important. The G7 continues to influence preparedness, research collaboration, and global health financing discussions. GCC countries are strengthening healthcare and biotechnology capabilities through coordinated investment and infrastructure development. NATO members contribute to preparedness planning, logistics, and resilience considerations, particularly where health security intersects with broader emergency response.

Country-Level Priorities Differ Across Research, Production, and Immunization Systems

Australia emphasizes research quality, regulatory oversight, and geographically resilient distribution. Brazil combines substantial public-health experience with priorities around domestic capability, procurement, and equitable access. Canada focuses on research partnerships, supply resilience, and national immunization coordination. China has major research, manufacturing, and public-health capabilities, alongside evolving regulatory and access priorities. France, Germany, Italy, and Spain operate within European coordination frameworks while maintaining distinct health-system and procurement considerations. India combines extensive vaccine manufacturing expertise with large-scale domestic and international public-health needs. Japan and South Korea emphasize advanced research, quality systems, and technology development. Mexico continues to prioritize access, surveillance, and production resilience. Russia’s landscape is shaped by domestic development and manufacturing priorities. The United Kingdom and United States retain strong research, regulatory, and clinical-development capabilities, with ongoing attention to preparedness, trust, and equitable delivery.

Industry Leaders Should Build Resilient, Evidence-Led mRNA Vaccine Platforms

Leaders should prioritize platform capabilities that improve stability, manufacturability, and adaptability while maintaining rigorous clinical and quality standards. They should diversify critical inputs, establish regional partnerships, and design supply chains for both routine demand and emergency response. Engagement with regulators and public-health agencies should begin early, especially for novel formulations, pediatric use, combination products, and new indications. Organizations should also invest in transparent safety communication, post-market surveillance, workforce development, and access-oriented contracting. AI initiatives should be governed through validation protocols, data-quality controls, cybersecurity safeguards, and clear accountability for human decisions.

Research Methodology for the mRNA Vaccines Executive Summary

This executive summary uses a structured qualitative assessment of the mRNA vaccine field, organized around technology development, clinical and regulatory considerations, manufacturing, access, public-health implementation, regional conditions, country capabilities, and international cooperation. Insights are framed from established characteristics of mRNA platforms and documented policy and industry priorities rather than unsupported numerical claims. The analysis deliberately excludes market estimates, market sizing, market shares, forecasts, and company-specific comparisons. Regional, group, and country observations are presented as contextual interpretations of infrastructure, research capacity, regulatory coordination, procurement, and delivery considerations.

The Next Phase Depends on Translation from Platform Potential to Durable Public-Health Value

mRNA vaccines have established a flexible technological foundation, but sustained impact will depend on practical performance across development, manufacturing, regulation, delivery, and public acceptance. Progress will require stronger evidence on durability and broader applications, more robust supply and cold-chain systems, and closer alignment between innovation and access. Organizations that combine scientific adaptability with quality discipline, regional collaboration, responsible AI use, and transparent communication will be best positioned to translate platform advances into dependable health outcomes.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. mRNA Vaccines Market, by Technology Type
7.1. Introduction
7.2. Lipid Nanoparticle (LNP) Platforms
7.3. Nucleoside-Modified mRNA Technologies
7.4. Self-Amplifying mRNA Platforms
8. mRNA Vaccines Market, by Route of Administration
8.1. Introduction
8.2. Inhalable mRNA Vaccines
8.3. Injectable mRNA Vaccines
8.4. Oral Delivery System
9. mRNA Vaccines Market, by Manufacturing Process
9.1. Introduction
9.2. Cell-Free Synthesis
9.3. In Vitro Transcription
10. mRNA Vaccines Market, by Vaccine Classification
10.1. Introduction
10.2. Preventive Vaccines
10.3. Therapeutic Vaccines
11. mRNA Vaccines Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Retail Pharmacies
12. mRNA Vaccines Market, by Age Group
12.1. Introduction
12.2. Adult
12.3. Geriatric
12.4. Pediatric
13. mRNA Vaccines Market, by Application
13.1. Introduction
13.2. Autoimmune Diseases
13.3. Infectious Diseases
13.3.1. COVID-19
13.3.2. Cytomegalovirus (CMV)
13.3.3. Ebola
13.3.4. HIV
13.3.5. Influenza
13.3.6. Rabies
13.3.7. Tuberculosis
13.3.8. Zika Virus
13.4. Oncology
13.4.1. Breast Cancer
13.4.2. Glioblastoma
13.4.3. Melanoma
13.4.4. Non-Small Cell Lung Cancer (NSCLC)
13.4.5. Ovarian Cancer
13.4.6. Pancreatic Cancer
13.4.7. Prostate Cancer
13.5. Rare Genetic Disorders
14. mRNA Vaccines Market, by Region
14.1. Introduction
14.2. Asia-Pacific
14.3. North America
14.4. Latin America
14.5. Europe
14.6. Middle East
14.7. Africa
15. mRNA Vaccines Market, by Group
15.1. Introduction
15.2. ASEAN
15.3. GCC
15.4. European Union
15.5. BRICS
15.6. G7
15.7. NATO
16. mRNA Vaccines Market, by Country
16.1. Introduction
16.2. United States
16.3. Germany
16.4. China
16.5. United Kingdom
16.6. India
16.7. Japan
16.8. Russia
16.9. Brazil
16.10. Canada
16.11. Italy
16.12. Mexico
16.13. France
16.14. Spain
16.15. Australia
16.16. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
17.2.1. Concentration Ratio (CR)
17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Acuitas Therapeutics Inc.
18.2. Alnylam Pharmaceuticals, Inc.
18.3. Arcturus Therapeutics Holdings Inc.
18.4. AstraZeneca PLC
18.5. Bavarian Nordic AS
18.6. BioNTech SE
18.7. Catalent, Inc.
18.8. Chongqing Zhifei Biological Products Co.,Ltd.
18.9. CureVac N.V.
18.10. Daiichi Sankyo Company, Limited
18.11. Eli Lilly and Company
18.12. Ethris GmbH
18.13. Gennova Biopharmaceuticals Limited.
18.14. GlaxoSmithKline PLC
18.15. Inovio Pharmaceuticals, Inc.
18.16. Johnson & Johnson Services, Inc.
18.17. Laboratorios Farmacéuticos Rovi, S.A.
18.18. Lonza Group AG
18.19. Merck & Co., Inc.
18.20. Moderna Inc.
18.21. Novartis AG
18.22. Pfizer Inc.
18.23. Recipharm AB
18.24. Regeneron Pharmaceuticals, Inc.
18.25. Roche Holding AG
18.26. Sanofi S.A.
18.27. Sartorius AG
18.28. Sinovac Biotech Ltd.
18.29. Takeda Pharmaceutical Company Limited
18.30. Thermo Fisher Scientific Inc.
18.31. Vertex Pharmaceuticals Incorporated
19. Key Experts
LIST OF FIGURES
FIGURE 1. Global mRNA Vaccines Market, Years Considered for the Study
FIGURE 2. Global mRNA Vaccines Market, Research Design
FIGURE 3. Global mRNA Vaccines Market, Research Framework
FIGURE 4. Global mRNA Vaccines Market, Data Triangulation
FIGURE 5. Global mRNA Vaccines Market Size, 2017-2032 (USD Million)
FIGURE 6. Global mRNA Vaccines Market Size, by Technology Type, 2025 vs 2032 (%)
FIGURE 7. Global mRNA Vaccines Market Size, by Technology Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global mRNA Vaccines Market Size, by Route of Administration, 2025 vs 2032 (%)
FIGURE 9. Global mRNA Vaccines Market Size, by Route of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global mRNA Vaccines Market Size, by Manufacturing Process, 2025 vs 2032 (%)
FIGURE 11. Global mRNA Vaccines Market Size, by Manufacturing Process, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global mRNA Vaccines Market Size, by Vaccine Classification, 2025 vs 2032 (%)
FIGURE 13. Global mRNA Vaccines Market Size, by Vaccine Classification, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global mRNA Vaccines Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global mRNA Vaccines Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global mRNA Vaccines Market Size, by Age Group, 2025 vs 2032 (%)
FIGURE 17. Global mRNA Vaccines Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global mRNA Vaccines Market Size, by Application, 2025 vs 2032 (%)
FIGURE 19. Global mRNA Vaccines Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global mRNA Vaccines Market Size, by Region, 2025 vs 2032 (%)
FIGURE 21. Global mRNA Vaccines Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global mRNA Vaccines Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global mRNA Vaccines Market Size, by Country, 2025 vs 2032 (%)
FIGURE 24. Global mRNA Vaccines Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global mRNA Vaccines Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global mRNA Vaccines Market Segmentation & Coverage
TABLE 2. Global mRNA Vaccines Market Size, 2017-2032 (USD Million)
TABLE 3. Global mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 4. Global Lipid Nanoparticle (LNP) Platforms Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Lipid Nanoparticle (LNP) Platforms Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Lipid Nanoparticle (LNP) Platforms Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Nucleoside-Modified mRNA Technologies Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Nucleoside-Modified mRNA Technologies Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Nucleoside-Modified mRNA Technologies Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Self-Amplifying mRNA Platforms Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Self-Amplifying mRNA Platforms Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Self-Amplifying mRNA Platforms Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 14. Global Inhalable mRNA Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Inhalable mRNA Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Inhalable mRNA Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Injectable mRNA Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Injectable mRNA Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Injectable mRNA Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Oral Delivery System Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Oral Delivery System Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Oral Delivery System Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 24. Global Cell-Free Synthesis Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Cell-Free Synthesis Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Cell-Free Synthesis Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global In Vitro Transcription Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global In Vitro Transcription Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global In Vitro Transcription Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 31. Global Preventive Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Preventive Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Preventive Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Therapeutic Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Therapeutic Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Therapeutic Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 38. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 45. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 55. Global Autoimmune Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Autoimmune Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Autoimmune Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global COVID-19 Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global COVID-19 Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global COVID-19 Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Cytomegalovirus (CMV) Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Cytomegalovirus (CMV) Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Cytomegalovirus (CMV) Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Ebola Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Ebola Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Ebola Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global HIV Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global HIV Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global HIV Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Influenza Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Influenza Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Influenza Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Rabies Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Rabies Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Rabies Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Tuberculosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Tuberculosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Tuberculosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Zika Virus Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Zika Virus Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Zika Virus Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Glioblastoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Glioblastoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Glioblastoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Melanoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Non-Small Cell Lung Cancer (NSCLC) Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Non-Small Cell Lung Cancer (NSCLC) Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Non-Small Cell Lung Cancer (NSCLC) Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Ovarian Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Ovarian Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Ovarian Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Pancreatic Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Pancreatic Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Pancreatic Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Rare Genetic Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Rare Genetic Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Rare Genetic Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global mRNA Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Asia-Pacific mRNA Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Asia-Pacific mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 115. Asia-Pacific mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 116. Asia-Pacific mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 117. Asia-Pacific mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 118. Asia-Pacific mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 119. Asia-Pacific mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 120. Asia-Pacific mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 121. Asia-Pacific mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 122. Asia-Pacific mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 123. North America mRNA Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 124. North America mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 125. North America mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 126. North America mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 127. North America mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 128. North America mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. North America mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 130. North America mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 131. North America mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 132. North America mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 133. Latin America mRNA Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 134. Latin America mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 135. Latin America mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 136. Latin America mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 137. Latin America mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 138. Latin America mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 139. Latin America mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 140. Latin America mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 141. Latin America mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 142. Latin America mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 143. Europe mRNA Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 144. Europe mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 145. Europe mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 146. Europe mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 147. Europe mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 148. Europe mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 149. Europe mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 150. Europe mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 151. Europe mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 152. Europe mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 153. Middle East mRNA Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 154. Middle East mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 155. Middle East mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 156. Middle East mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 157. Middle East mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 158. Middle East mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 159. Middle East mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 160. Middle East mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 161. Middle East mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 162. Middle East mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 163. Africa mRNA Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 164. Africa mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 165. Africa mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 166. Africa mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 167. Africa mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 168. Africa mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 169. Africa mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 170. Africa mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 171. Africa mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 172. Africa mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 173. Global mRNA Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 174. ASEAN mRNA Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 175. ASEAN mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 176. ASEAN mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 177. ASEAN mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 178. ASEAN mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 179. ASEAN mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 180. ASEAN mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 181. ASEAN mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 182. ASEAN mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 183. ASEAN mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 184. GCC mRNA Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 185. GCC mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 186. GCC mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 187. GCC mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 188. GCC mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 189. GCC mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 190. GCC mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 191. GCC mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 192. GCC mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 193. GCC mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 194. European Union mRNA Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 195. European Union mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 196. European Union mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 197. European Union mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 198. European Union mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 199. European Union mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 200. European Union mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 201. European Union mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 202. European Union mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 203. European Union mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 204. BRICS mRNA Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 205. BRICS mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 206. BRICS mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 207. BRICS mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 208. BRICS mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 209. BRICS mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 210. BRICS mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 211. BRICS mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 212. BRICS mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 213. BRICS mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 214. G7 mRNA Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 215. G7 mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 216. G7 mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 217. G7 mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 218. G7 mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 219. G7 mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 220. G7 mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 221. G7 mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 222. G7 mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 223. G7 mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 224. NATO mRNA Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 225. NATO mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 226. NATO mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 227. NATO mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 228. NATO mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 229. NATO mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 230. NATO mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 231. NATO mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 232. NATO mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 233. NATO mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 234. Global mRNA Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 235. United States mRNA Vaccines Market Size, 2017-2032 (USD Million)
TABLE 236. United States mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 237. United States mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 238. United States mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 239. United States mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 240. United States mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 241. United States mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 242. United States mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 243. United States mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 244. United States mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 245. Germany mRNA Vaccines Market Size, 2017-2032 (USD Million)
TABLE 246. Germany mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 247. Germany mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 248. Germany mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 249. Germany mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 250. Germany mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 251. Germany mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 252. Germany mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 253. Germany mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 254. Germany mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 255. China mRNA Vaccines Market Size, 2017-2032 (USD Million)
TABLE 256. China mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 257. China mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 258. China mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 259. China mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 260. China mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 261. China mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 262. China mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 263. China mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 264. China mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 265. United Kingdom mRNA Vaccines Market Size, 2017-2032 (USD Million)
TABLE 266. United Kingdom mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 267. United Kingdom mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 268. United Kingdom mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 269. United Kingdom mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 270. United Kingdom mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 271. United Kingdom mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 272. United Kingdom mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 273. United Kingdom mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 274. United Kingdom mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 275. India mRNA Vaccines Market Size, 2017-2032 (USD Million)
TABLE 276. India mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 277. India mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 278. India mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 279. India mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 280. India mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 281. India mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 282. India mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 283. India mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 284. India mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 285. Japan mRNA Vaccines Market Size, 2017-2032 (USD Million)
TABLE 286. Japan mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 287. Japan mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 288. Japan mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 289. Japan mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 290. Japan mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 291. Japan mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 292. Japan mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 293. Japan mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 294. Japan mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 295. Russia mRNA Vaccines Market Size, 2017-2032 (USD Million)
TABLE 296. Russia mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 297. Russia mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 298. Russia mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 299. Russia mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 300. Russia mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 301. Russia mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 302. Russia mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 303. Russia mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 304. Russia mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 305. Brazil mRNA Vaccines Market Size, 2017-2032 (USD Million)
TABLE 306. Brazil mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 307. Brazil mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 308. Brazil mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 309. Brazil mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 310. Brazil mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 311. Brazil mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 312. Brazil mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 313. Brazil mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 314. Brazil mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 315. Canada mRNA Vaccines Market Size, 2017-2032 (USD Million)
TABLE 316. Canada mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 317. Canada mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 318. Canada mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 319. Canada mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 320. Canada mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 321. Canada mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 322. Canada mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 323. Canada mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 324. Canada mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 325. Italy mRNA Vaccines Market Size, 2017-2032 (USD Million)
TABLE 326. Italy mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 327. Italy mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 328. Italy mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 329. Italy mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 330. Italy mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 331. Italy mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 332. Italy mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 333. Italy mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 334. Italy mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 335. Mexico mRNA Vaccines Market Size, 2017-2032 (USD Million)
TABLE 336. Mexico mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 337. Mexico mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 338. Mexico mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 339. Mexico mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 340. Mexico mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 341. Mexico mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 342. Mexico mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 343. Mexico mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 344. Mexico mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 345. France mRNA Vaccines Market Size, 2017-2032 (USD Million)
TABLE 346. France mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 347. France mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 348. France mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 349. France mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 350. France mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 351. France mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 352. France mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 353. France mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 354. France mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 355. Spain mRNA Vaccines Market Size, 2017-2032 (USD Million)
TABLE 356. Spain mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 357. Spain mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 358. Spain mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 359. Spain mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 360. Spain mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 361. Spain mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 362. Spain mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 363. Spain mRNA Vaccines Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 364. Spain mRNA Vaccines Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 365. Australia mRNA Vaccines Market Size, 2017-2032 (USD Million)
TABLE 366. Australia mRNA Vaccines Market Size, by Technology Type, 2017-2032 (USD Million)
TABLE 367. Australia mRNA Vaccines Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 368. Australia mRNA Vaccines Market Size, by Manufacturing Process, 2017-2032 (USD Million)
TABLE 369. Australia mRNA Vaccines Market Size, by Vaccine Classification, 2017-2032 (USD Million)
TABLE 370. Australia mRNA Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 371. Australia mRNA Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 372. Australia mRNA Vaccines Market Size, by Application, 2017-2032 (USD Million)
TABLE 373. Australia mRNA Vaccines Market Size, by Infectious Diseases, 2017-20

Companies Mentioned

  • Acuitas Therapeutics Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • AstraZeneca PLC
  • Bavarian Nordic AS
  • BioNTech SE
  • Catalent, Inc.
  • Chongqing Zhifei Biological Products Co.,Ltd.
  • CureVac N.V.
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Ethris GmbH
  • Gennova Biopharmaceuticals Limited.
  • GlaxoSmithKline PLC
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Laboratorios Farmacéuticos Rovi, S.A.
  • Lonza Group AG
  • Merck & Co., Inc.
  • Moderna Inc.
  • Novartis AG
  • Pfizer Inc.
  • Recipharm AB
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sartorius AG
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Incorporated

Related Topics

Related Reports

mRNA Vaccine Drugs Development Services Market - Global Forecast 2026-2032 - Product Image

mRNA Vaccine Drugs Development Services Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
mRNA Vaccine Raw Materials Market - Global Forecast 2026-2032 - Product Image

mRNA Vaccine Raw Materials Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
mRNA Vaccines and Therapeutics Market Size, Share, Trends and Forecast by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-User, and Region 2026-2034 - Product Image

mRNA Vaccines and Therapeutics Market Size, Share, Trends and Forecast by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-User, and Region 2026-2034

  • Report
  • 146 Pages
  • Global
From
mRNA Vaccine and Therapeutics Market (4th Edition) by Application Area, Target Disease Indication and Geographical Regions - Trends and Forecast, Till 2035 - Product Image

mRNA Vaccine and Therapeutics Market (4th Edition) by Application Area, Target Disease Indication and Geographical Regions - Trends and Forecast, Till 2035

  • Report
  • 553 Pages
  • Global
From
mRNA Vaccine Market Outlook 2026-2034: Market Share, and Growth Analysis by Application, End User, Type, Technology - Product Image

mRNA Vaccine Market Outlook 2026-2034: Market Share, and Growth Analysis by Application, End User, Type, Technology

  • Report
  • 160 Pages
  • Global
From

About the mRNA Vaccines Market

In the landscape of vaccines, mRNA (messenger RNA) vaccines represent a novel technology that has garnered substantial attention for its role in rapid vaccine development. These vaccines operate by instructing cells to produce a protein that triggers an immune response without using a live virus. This innovative approach stands out for its ability to be developed and scaled up swiftly in response to infectious diseases, offering a flexible platform for vaccine creation. While traditional vaccine development may take years of research and testing, mRNA vaccines can be designed once the genetic information of a pathogen is known. The adoption of mRNA vaccines has been driven by their potential to address a broad spectrum of diseases beyond just infectious agents. Research is being conducted into their applicability in treating and preventing cancers, genetic disorders, and autoimmune diseases. This expansion of mRNA technology into various medical domains has contributed to the diversification of the vaccine industry. Several prominent companies are active in the mRNA vaccines market, shaping its trajectory with their research and development efforts. Notable firms include Moderna, Pfizer in collaboration with BioNTech, and CureVac. These companies have invested heavily in mRNA technology, leading to advances that have solidified their positions as key players in the pharmaceutical and biotechnology sectors. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.